Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22077666 | 1.00 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL13074797 | 0.84 | CYP1A2 (0.30) | — | |
| SCHEMBL10212414 | 0.82 | — | — | |
| SCHEMBL13260909 | 0.80 | HMGCR (0.41) | — | |
| SCHEMBL9287478 | 0.79 | TOP2A (0.39) | — | |
| SCHEMBL19676622 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2 | |
| SCHEMBL10328064 | 0.73 | — | — | |
| SCHEMBL7952252 | 0.73 | — | — | |
| SCHEMBL19493420 | 0.73 | — | — | |
| SCHEMBL18536367 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200606-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| EP-3133071-A1 | C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai De Novo Pharmatech Co Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-2324002-B1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS SUB LLC (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016070740-A1 | A CLASS OF NEW TYPE SGLT2 INHIBITOR COMPOUND AND A PHARMACEUTICAL COMPOSITION THEREOF | 镇江新元素医药科技有限公司 | 2016-05-12 | — | — | WO | disclosed |
| WO-2015132803-A2 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-09-11 | — | — | WO | disclosed |
| US-8575321-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012165914-A2 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
| US-8106021-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7803778-B2 | Glucose transport inhibitors and methods of use | THERACOS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2010022313-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010009243-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207661-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SMN1; SMN2 3758/4885 |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SMN1; SMN2 3758/4885 |
| US-20120329732-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SMN1; SMN2 3758/4885 |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A1 | SMN1; SMN2 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.